Platelet alpha- and beta- secretase activities are not significantly affected by dementia or mild cognitive impairment in Swedish patients

Current Alzheimer Research

Volumn 7, Issue 2, 2010, Pages 134-139

  Gorham, P ^a,b   Bark, N ^a   Meaney, S ^b   Bjorkhem I ^a   Crisby, M ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b DUBLIN INSTITUTE OF TECHNOLOGY   (Ireland)

Author keywords

secretase; secretase; Alzheimer's disease; Biomarkers

Indexed keywords

ALPHA SECRETASE; BETA SECRETASE; TRIACYLGLYCEROL;

ALZHEIMER DISEASE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; DISEASE MARKER; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME ANALYSIS; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SWEDEN; THROMBOCYTE; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; BIOLOGICAL MARKERS; BLOOD PLATELETS; CELL MEMBRANE; COGNITION DISORDERS; COHORT STUDIES; ENZYME ASSAYS; HUMANS; MEMBRANE LIPIDS; SWEDEN; TRIGLYCERIDES;

EID: 77949749516     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720510790691254     Document Type: Article

References (34)

1. Kalaria RN, Maestre GE, Arizaga R, Friedland RP, Galasko D, Hall K, et al. Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors. Lancet Neurol 7: 812-26 (2008).
2. Heron M. Deaths: leading causes for 2004. Natl Vital Stat Rep 56: 1-95 (2007).
3. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81: 741-66 (2001).
4. Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120: 885-90 (1984).
5. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and down syndrome. Proc Natl Acad Sci USA 82: 4245-9 (1985).
6. Sisodia SS, Koo EH, Beyreuther K, Unterbeck A, Price DL. Evidence That β-amyloid protein in alzheimer's disease is not derived by normal processing. Science 248: 492-5 (1990).
7. Esch FS, Keim PS, Beattie EC, Blacher RW, Culwell AR, Oltersdorf T, et al. Cleavage of Amyloid β-peptide during constitutive processing of its precursor. Science 248: 1122-4 (1990).
8. Thornton E, Vink R, Blumbergs PC, Van Den Heuvel C. Soluble amyloid precursor protein α reduces neuronal injury and improves functional outcome following diffuse traumatic brain injury in rats. Brain Res 1094: 38-46 (2006).
9. Marks N, Berg MJ. Neurosecretases provide strategies to treat sporadic and familial Alzheimer disorders. Neurochem Intl 52: 184-215 (2008).
10. Tanabe C, Hotoda N, Sasagawa N, Sehara-Fujisawa A, Maruyama K, Ishiura S. ADAM19 is tightly associated with constitutive Alzheimer's disease APP α-secretase in A172 cells. Biochem Biophys Res Commun 352: 111-7 (2007).
11. Hussain I, Powell D, Howlett DR, Tew DG, Meek TD, Chapman C, et al. Identification of a novel aspartic protease (Asp 2) as β-secretase. Mol Cell Neurosci 14: 419-27 (1999).
12. Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, et al. Purification and cloning of amyloid precursor protein β-secretase from human brain. Nature 402: 537-40 (1999).
13. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, et al. β-Secretase cleavage of alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286: 735-41 (1999).
14. Farzan M, Schnitzler CE, Vasilieva N, Leung D, Choe H. BACE2, a β-secretase homolog, cleaves at the β site and within the amyloid-β region of the amyloid-β precursor protein. Proc Natl Acad Sci 97: 9712-17 (2000).
15. Yan R, Munzner JB, Shuck ME, Bienkowski MJ. BACE2 Functions as an alternative α-secretase in cells. J Biol Chem 276: 34019-27 (2001).
16. Basi G, Frigon N, Barbour R, Doan T, Gordon G, McConlogue L, et al. Antagonistic effects of β-site amyloid precursor protein-cleaving enzymes 1 and 2 on β-amyloid peptide production in cells. J Biol Chem 278: 31512-20 (2003).
17. Holsinger D, McLean CA, Beyreuther K, Masters CL, Evin G. Increased expression of the amyloid precursor β-secretase in Alzheimer's disease. annNeurol 51: 783-6 (2002).
18. Fukumoto H, Cheung BS, Hyman BT, Irizarry MC. β-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol 59: 1381-9 (2002).
19. Tyler SJ, Dawbarn D, Wilcock GK, Allen SJ. α- and β-secretase: profound changes in Alzheimer's disease. Biochem Biophys Res Commun 299: 373-6 (2002).
20. Harada H, Tamaoka A, Ishii K, Shoji S, Kametaka S, Kametani F, et al. β-site APP cleaving enzyme 1 (BACE1) is increased in remaining neurons in Alzheimer's disease brains. Neurosci Res 54: 24-9 (2006).
21. Chen M, Inestrosa NC, Ross GS, Fernandez HL. Platelets are the primary source of amyloid β-peptide in human blood. Biochem Biophys Res Commun 213: 96-103 (1995).
22. Johnston JA, Liu WW, Coulson DTR, Todd S, Murphy S, Brennan S, et al. Platelet β-secretase activity is increased in Alzheimer's disease. Neurobiol Aging 29: 661-8 (2008).
23. Tang K, Hynan LS, Baskin F, Rosenberg RN. Platelet amyloid precursor protein processing: a bio-marker for Alzheimer's disease. J Neurol Sci 240: 53-8 (2006).
24. Colciaghi F, Borroni B, Pastorino L, Marcello E, Zimmermann M, Cattabeni F, et al. α-Secretase ADAM10 as well as αAPPs Is reduced in platelets and CSF of Alzheimer disease patients. Mol Med 8: 67-74 (2002).
25. Skovronsky DM, Blaine Moore D, Milla ME, Doms RW, Lee VMY. Protein kinase C-dependent α-secretase competes with β-secretase for cleavage of amyloid-β precursor protein in the transgolgi network. J Biol Chem 275: 2568-75 (2000).
26. Zhong Z, Ewers M, Teipel S, Bürger K, Wallin A, Blennow K, et al. Levels of β-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Arch Gen Psychiatry 64: 718-26 (2007).
27. Liu WW, Todd S, Craig D, Passmore AP, Coulson DT, Murphy S, et al. Elevated platelet β-secretase activity in mild cognitive impairment. Dement Geriatr Cogn Disord 24: 464-8 (2007).
28. Grimm MO, Grimm HS, Tomic I, Beyreuther K, Hartmann T, Bergmann C. Independent inhibition of Alzheimer disease β- and γ-secretase cleavage by lowered cholesterol levels. J Biol Chem 283: 11302-11 (2008).
29. Kojro E, Gimpl G, Lammich S, März W, Fahrenholz F. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM 10. Proc Natl Acad Sci USA 98: 5815-20 (2001).
30. Liu WW, Todd S, Coulson DT, Irvine GB, Passmore AP, McGuinness B, et al. A novel reciprocal and biphasic relationship between membrane cholesterol and β-secretase activity in SH-SY5Y cells and in human platelets. J Neurochem 108: 341-9 (2009).
31. Tanabe C, Ebina M, Asai M, Futai E, Sasagawa N, Katano K, et al. 1,3-Capryloyl-2-arachidonoyl glycerol activates α-secretase activity and suppresses Aß40 secretion in A172 cells. Neurosci Lett 450: 324-6 (2009).
32. Tachida Y, Nakagawa K, Saito T, Saido TC, Honda T, Saito Y, et al. Interleukin-1β up-regulates TACE to enhance α-cleavage of APP in neurons: resulting decrease in Aβ production. J Neurochem 104: 1387-93 (2008).
33. Bandyopadhyay S, Hartley DM, Cahill CM, Lahiri DK, Chattopadhyay N, Rogers JT. Interleukin-1α stimulates nonamyloidogenic pathway by α-secretase (ADAM-10 and ADAM-17) cleavage of APP in human astrocytic cells involving p38 MAP kinase. J Neurosci Res 84: 106-18 (2006).
34. Licastro F, Pedrini S, Caputo L, Annoni G, Davis LJ, Ferri C, et al. Increased plasma levels of interleukin-1, interleukin-6 and α-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain? J Neuroimmunol 103: 97-102 (2000).